HomeTechnologyStopped manufacturing, supply of additional Covishield doses, disclosed all side effects: Serum...

Stopped manufacturing, supply of additional Covishield doses, disclosed all side effects: Serum Institute

Stopped manufacturing, supply of additional Covishield doses,
 disclosed all side effects: Serum Institute

New Delhi, May 8 (IANS) As British-Swedish pharma giant AstraZeneca recalled its Covid-19 vaccine globally, Pune-based Serum Institute of India (SII) on Wednesday said it stopped the manufacturing and supply of additional doses of Covishield in December 2021.

AstraZeneca has voluntarily withdrawn the “marketing authorisation” of its Covid vaccine, sold as Covishield in India and Vaxzevria in Europe.

In a statement to IANS, an SII spokesperson said that with India achieving high vaccination rates in 2021 and 2022, coupled with the emergence of new mutant variant strains, the demand for previous vaccines diminished significantly.

“Consequently, since December 2021, we have stopped the manufacturing and supply of additional doses of Covishield,” the spokesperson added.

The Serum Institute said that they fully understand the ongoing concerns and “it’s crucial to emphasise our commitment to transparency and safety”.

The company said that from the outset, “we have disclosed all rare to very rare side effects, including Thrombosis with Thrombocytopenia Syndrome, in the packaging insert in 2021”.

Thrombotic Thrombocytopenic Syndrome (TTS) is a rare side effect that can cause people to have blood clots and a low blood platelet count, linked to at least 81 deaths in the UK as well as hundreds of serious injuries.

The SII stressed that despite the challenges faced during the global pandemic, the safety of the vaccine remains paramount.

“Regardless of whether it’s AstraZeneca’s Vaxzervria or our own Covishield, both vaccines have been instrumental in saving millions of lives worldwide.

“We commend the collaborative efforts of governments and ministries in facilitating a unified global response to the pandemic,” added the Serum Institute.

Meanwhile, the British-Swedish multinational pharmaceutical is also being sued by more than 50 alleged victims and grieving relatives in a High Court case in the UK.

–IANS

na/svn

Go to Source

Disclaimer

The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

For any legal details or query please visit original source link given with news or click on Go to Source.

Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.

If you are not willing to accept this disclaimer then we recommend reading news post in its original language.

RELATED ARTICLES
- Advertisment -

Most Popular